Selecta Biosciences (NASDAQ:SELB) completed enrollment in its Phase 2 COMPARE trial of SEL-212 for the treatment of chronic refractory gout.
SEL-212 is designed to sustain control of serum uric acid (SUA) levels in chronic refractory gout patients. It consists of pegadricase, Selecta’s proprietary pegylated uricase, and ImmTOR, which is designed to mitigate the formation of anti-drug antibodies.
The trial enrolled 150 patients and will evaluate the superiority of a once-monthly dose of SEL-212 versus a bi-weekly dose of pegloticase, the current FDA-approved therapy. The primary endpoint is maintenance of SUA levels of less than 6mg/dL at three and six months. Topline data is expected by mid-2020.
“We are confident that the COMPARE trial will build on the already robust body of SEL-212 data which showed its ability to achieve SUA levels below 6mg/dL, and further the clinical development program for this important therapeutic,” Carsten Brunn, president and CEO, said in a statement.
